Replies to post #204559 on Biotech Values

[JohnWayne]

Ah good point, I'd forgotten about that. I'm not familiar enough with Humira's IP to have a sense for likelihood of at-risk launch...

[DewDiligence]

AMGN’s PR on FDA approval of Amjeta (Humira FoB):

http://finance.yahoo.com/news/fda-approves-amgens-amjevita-adalimumab-220300537.html

[DewDiligence]

(ABBV/MNTA/etc)—AMGN not launching Amjevita—(Humira FoB)—until 2018 or later:

Relevant to $MNTA. https://t.co/XHbmBsL9ul

— Roy Friedman (@DewDiligence) October 27, 2016